Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 9/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.62 |
| ▸ | HTR3B | O95264 | 4/20 | 0.62 |
| ▸ | HTR3A | P46098 | 4/20 | 0.62 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.62 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.62 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2959681 | 0.98 | ADRB1 (0.96) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Piperazine SCHEMBL28293494 | 0.98 | ADRB1 (0.96) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2984679 | 0.85 | ADRB1 (0.73) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL11473295 | 0.83 | ADRB1 (0.69) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL11297420 | 0.83 | ADRB1 (0.71) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL30609706 | 0.83 | ADRB1 (0.71) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL232655 | 0.83 | ADRB1 (0.71) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL30609657 | 0.83 | ADRB1 (0.71) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2738997 | 0.83 | ADRB1 (0.71) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL1186845 | 0.83 | ADRB1 (0.71) | ADRB1HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 970 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111879767-B | Color development test method of piperazine novel mental active substance | 福建警察学院 | 2022-05-03 | — | — | CN | claimed |
| CN-111795963-B | Method for chromogenic detection of piperazine novel psychotropic active substances | 福建警察学院 | 2022-05-03 | — | — | CN | claimed |
| CN-111879767-A | Color development test method of piperazine novel mental active substance | 福建警察学院 | 2020-11-03 | — | — | CN | claimed |
| CN-111795963-A | Method for chromogenic detection of piperazine novel psychotropic active substances | 福建警察学院 | 2020-10-20 | — | — | CN | claimed |
| CN-105777731-B | The bridged piperazine derivatives and its preparation method and application of Han You oxadiazoles | 山东理工大学 | 2018-10-16 | — | — | CN | claimed |
| CN-108558986-A | Enoxolone analog derivative containing piperazine structure and preparation method thereof and purposes | 亿利耐雀生物科技有限公司 | 2018-09-21 | — | — | CN | claimed |
| CN-104230915-B | Phenylpiperazine derivatives containing thiazolidinedione and preparation method thereof and purposes | 南京大学 | 2016-08-17 | — | — | CN | claimed |
| CN-105777731-A | Oxadiazole-containing piperazine derivative as well as preparation method and use thereof | 山东理工大学 | 2016-07-20 | — | — | CN | claimed |
| CN-104046246-B | The chemical-mechanical planarization of tungsten-containing substrate | 气体产品与化学公司 | 2016-06-15 | — | — | CN | claimed |
| CN-103797022-B | The method of purification of betulonic acid and Boc-Methionin betulonic acid, and utilize bridged piperazine derivatives to prepare the methodology of organic synthesis of betulonic acid acid amides | KOREA INSTITUTE OF ENERGY RESEARCH (KR) | 2016-04-20 | — | — | CN | claimed |
| US-20080076776-A1 | Therapeutic compounds | BIOVITRUM AB (SE) | 2008-03-27 | — | — | US | claimed |
| WO-2008000745-A2 | ADENOSINE DERIVATIVES FOR THE TREATMENT OF PAIN | BIOVITRUM AB (PUBL) (SE) | 2008-01-03 | — | — | WO | claimed |
| JP-2000506513-A | — | — | 2000-05-30 | — | — | JP | claimed |
| EP-0880532-A4 | NON-NUCLEOTIDE PHOSPHOROUS ESTER OLIGOMERS | PHARMAGENICS INC (US) | 1999-06-09 | — | — | EP | claimed |
| EP-0880532-A1 | NON-NUCLEOTIDE PHOSPHOROUS ESTER OLIGOMERS | PHARMAGENICS, INC. (US) | 1998-12-02 | — | — | EP | claimed |
| EP-0804443-A4 | NON-NUCLEOTIDE PHOSPHORUS ESTER OLIGOMERS | PHARMAGENICS INC (US) | 1998-04-29 | — | — | EP | claimed |
| EP-0804443-A1 | NON-NUCLEOTIDE PHOSPHORUS ESTER OLIGOMERS | PHARMAGENICS, INC. (US) | 1997-11-05 | — | — | EP | claimed |
| WO-1997028168-A1 | NON-NUCLEOTIDE PHOSPHOROUS ESTER OLIGOMERS | PHARMAGENICS, INC. (US) | 1997-08-07 | — | — | WO | claimed |
| WO-1996022297-A9 | NON-NUCLEOTIDE PHOSPHORUS ESTER OLIGOMERS | — | 1996-10-03 | — | — | WO | claimed |
| WO-1996022297-A1 | NON-NUCLEOTIDE PHOSPHORUS ESTER OLIGOMERS | PHARMAGENICS, INC. (US) | 1996-07-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076776-A1 | Therapeutic compounds | FPR3, OGFR, OPRK1 | ADRB1 453/4885HTR3E 262/4885HTR3B 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.